UNSPSC 51432004: Guggulsterone

This classification denotes an antihypertensive agent with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34969JX79R, chemically known as (8R,9S,10R,13S,14S,17E)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione, which bears US NIH Compound Identifier 6439929. As of Q4 2014, GUGGULSTERONE remains the US FDA Preferred Term for this commodity. SMILES: CC=C1C(=O)CC2C1(CCC3C2CCC4=CC(=O)CCC34C)C.

UNSPSC 51432004 Guggulsterone is a Commodity code nominally describing a botanical extract used in dietary supplements and traditional medicine preparations. However, state and local procurement activity under this code does not reflect that scope; instead, recent solicitations tag emergency medical medications, generic pharmaceuticals, and over-the-counter products under the guggulsterone designation, indicating either a data taxonomy misalignment or administrative coding error at the source level. The actual work being solicited under the code involves supply of critical care medications for emergency medical services, generic multi-source pharmaceutical products for government facilities, and pharmacy benefit program infrastructure. Issuing bodies include city purchasing departments (Tampa Fire Rescue procurement through the City of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing organizations spanning multiple states (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across Minnesota and Oregon).

Recent activity concentrates in the South and Midwest. The City of Tampa issued an Invitation for Bids (26P00188) on April 24, 2026, with response due April 8, 2026, for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem totaling an estimated contract value of $40,000, with a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission released a Request for Information (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program, a preliminary market-intelligence phase without stated budget or award values. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing vehicle, issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with contract effectiveness July 1, 2026, and no specific award values disclosed. The code shows active state and local procurement but requires verification that tagged opportunities are genuinely within guggulsterone scope or reflect upstream coding errors.